RxDoctor Payments Data

Maged Habib, MD

Ophthalmology · Boynton Beach, FLNPI 1508867540

Payments from drug & device makers

$4,730in general payments, 2019–2025

Across 94 payments — averaging $50.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Alcon$744
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$470
  • Bausch & Lomb Americas Inc.$445
  • Johnson & Johnson Surgical Vision, Inc.$354
  • Sight Sciences, Inc.$228
  • plus $1K from 18 others

What the payments were for

  • Food & beverage$4,69199%
  • Gifts$391%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,730 in reported general payments places this provider in the 70th percentile of 1,405 ophthalmology providers in Florida.

See all ophthalmology providers in Florida

Medicare billing

Part B allowed, 2024
$434,015
Medicare patients
614
Services billed
10,281

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost342$157,956
RestasisCyclosporine133$129,639
Travoprost286$46,264
RocklatanNetarsudil Mesylat/Latanoprost116$44,069
CombiganBrimonidine Tartrate/Timolol116$40,529
CequaCyclosporine53$35,358
XiidraLifitegrast44$34,044
Fluorometholone379$24,604
MieboPerfluorohexyloctane/Pf27$20,007
VyzultaLatanoprostene Bunod65$18,846
Cyclosporine42$16,773
Timolol Maleate197$15,641
VevyeCyclosporine11$9,592
BesivanceBesifloxacin Hcl38$9,136
SimbrinzaBrinzolamide/Brimonidine Tart26$8,482

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis, Combigan, Alphagan P$1,145$332,224602 claims
Bausch & Lomb Americas Inc.Xiidra, Miebo, Vyzulta$445$72,897136 claims
Aerie Pharmaceuticals, Inc.Rocklatan$36$44,069116 claims
Sun Pharmaceutical Industries Inc.Cequa$30$35,35853 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCBesivance, Prolensa, Lotemax Sm$470$23,23587 claims
Harrow Eye, LLCVevye$94$9,59211 claims
AlconSimbrinza$744$8,48226 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,405 ophthalmology providers in Florida.

Other ophthalmology in Boynton Beach

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →